Live·Verified funding discovery · 2026.2
874 grants · 19 open · 435 companies · 2640 concepts874 / 19 / 435 / 2640
COMPANIESCompanies rated · 435 (no change)PROJECTSProjects rated · 70 (no change)CATALOGUE874 grants in catalogue · 19 open right nowPOWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CACOMPANIESCompanies rated · 435 (no change)PROJECTSProjects rated · 70 (no change)CATALOGUE874 grants in catalogue · 19 open right nowPOWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA
← Back to projectsResearch & Funding Infrastructure

Singularis: reforming the communication of scientific knowledge

Research & Funding InfrastructureLast rated 5/30/2026CommercialCanonical source ↗

Singularis is an early-stage scientific-knowledge platform that argues conventional papers are a bottleneck for both human readers and AI systems, and proposes converting papers into structured argumentation graphs and nanopublication-like units that link hypotheses, methods, results, conclusions, and evidence. The concrete product evidence is a beta system for PDF upload, knowledge-graph visualization, and graph-based chat, plus public claims about AI-generated paper graphs and source-linked annotations. The core idea is plausible as research infrastructure, but current evidence shows positioning and prototype functionality more clearly than validated accuracy, adoption, or field-level impact.

Source coverage

17 sources searched, 74 evidence rows (46 with full text)
Team project1Project page1Project page crawl0PubMed8Semantic Scholar0OpenAlex4arXiv0bioRxiv0Web search39News0YouTube0Wikipedia13GitHub0Author publications0Organization records1Patents (project-held)0Patents (field corridor)7

Scientific

Mechanism and evidence quality

45.9

Breakthrough

How much success could unlock

55.5

Investor

Deal-quality signals

47.0

Overall

Weighted composite

48.7

Where this project sits

Positioned against every public project across all sections

0255075100048121620LIFESPAN GAIN (YEARS, ESTIMATED)OVERALL SCOREmax in DB: 15 yr
BioreplacementBioinformationDrug & Molecule DiscoveryGenetic & Cellular TherapiesAging Biology ResearchDiagnostics & BiomarkersBrain & Cognitive LongevityResearch & Funding Infrastructure
Inner ring · capital to breakeven  ·  Outer ring · best-case upside multiple

Comprehensive brief

Hypothesis

Scientific communication can be made materially more efficient and reusable if the paper remains a coexistence layer while the underlying scientific content is represented as typed, linked graph objects that humans and AI can navigate directly.

Mechanism

The proposed mechanism is to annotate papers into argumentation graphs or nanopublication-like units so readers can inspect specific claims, evidence, experiments, and interpretations without reconstructing them from prose, while AI systems can use the same structure for search, validation, and cross-paper linking.

Approach

Singularis appears to be building an AI-assisted knowledge-graph platform around uploaded PDFs, graph visualization, and chat over graphs, with a longer-term plan to evolve from single-paper annotation toward field-level interconnected graphs, graph-based peer review, and alternative contribution metrics. The approach is explicitly evolutionary rather than disruptive at first, because the team acknowledges that papers and journal metrics still dominate academic incentives.

Status

Early stage and beta. Evidence supports a public-facing prototype with onboarding friction, public statements from cofounder Peter Lidsky in May 2026, and a 2026 Zenodo project publication signal, but does not show independent validation of graph accuracy, user retention, institutional uptake, or measurable workflow improvement.

Success criteria

Success would require showing that the system can convert papers into accurate, inspectable graphs at useful scale; that users find the graphs faster or clearer than strategic reading of prose; that graph nodes reliably link back to source passages; and that the platform can accumulate enough legacy and new content to become more than a single-paper annotation demo. Stronger evidence would include blinded accuracy checks, reproducibility or comprehension gains, and repeat usage by real researchers, students, clinicians, or R&D teams.

Near-term impact (1-3 yrs)

In the next 1-3 years, if the central claim holds, practical uses include faster structured reading of dense papers, source-grounded navigation from claims to supporting text, AI-assisted literature triage for scientists and students, and better internal knowledge capture for labs or R&D teams reading large literatures. It could also enable pilot workflows for graph-based peer review, paper annotation feedback loops, and limited cross-paper synthesis in domains where users are willing to tolerate imperfect AI extraction.

Future horizons (5-20 yrs)

Over 5-20 years, success would open a larger shift from paper-centric publishing to machine-actionable scientific knowledge systems: field-wide argumentation graphs, new citation and contribution metrics based on evidence structure rather than paper prestige, executable or continuously updated research objects, more granular peer review, and AI systems that can reason over scientific claims with provenance rather than only over prose. That could create new subfields around scientific-knowledge engineering, graph-native publishing, and agent-facing research infrastructure, but only if governance, incentives, and legacy-content migration problems are solved.

Breakthrough thesis

If Singularis can make paper-to-graph conversion accurate, inspectable, and easy enough to coexist with existing publishing, it could become a credible bridge from static papers to graph-native scientific communication and meaningfully improve how humans and AI consume, compare, and extend research.

Failure thesis

The project may stall because the hard part is not just graph technology but institutional adoption, annotation accuracy, and migration of legacy literature; without strong precision, clear user advantage, and integration into existing evaluation systems, it risks remaining an interesting beta visualization layer on top of papers rather than changing scientific communication.

Risk of failure

Technical78

Technical risk is high because the core claim depends on reliably converting narrative papers into accurate, inspectable argumentation graphs at useful scale, but the evidence only shows a beta interface and conceptual claims, not accuracy benchmarks, blinded evaluations, or evidence that graph nodes consistently map back to source passages. The team explicitly frames large-scale paper-to-structured-data migration as newly feasible because of AI, which underscores that automated extraction quality is central rather than solved.

Translational42

This is not a therapeutics or wet-lab program, so classic animal-to-human translation risk is limited. The main translation risk is product generalization across user types and workflows: the evidence supports a beta product and a hypothesis about faster comprehension, but not demonstrated uptake or measured performance gains across researchers, students, clinicians, or R&D teams.

Regulatory / jurisdictional28

Regulatory risk appears relatively low because the current product is a scientific-knowledge and annotation platform rather than a medical, diagnostic, or therapeutic system. The available evidence shows PDF upload, graph visualization, and chat over scientific content, with no evidence of patient-data handling, regulated clinical claims, or a novel approval pathway. There is still some medium-term governance/privacy exposure if the product expands into institutional or proprietary-document workflows, but that is not evidenced here.

Competitive dynamics74

Competitive risk is high because Singularis is entering an active scientific-communication and computable-knowledge area where multiple adjacent efforts already argue that static papers are inadequate and propose more structured, machine-actionable publishing or knowledge exchange formats. That does not disprove Singularis, but it means the conceptual territory is crowded and the project could be outrun by better-funded tooling, publishing-platform incumbents, or broader agent-native research artifact approaches before it establishes a defensible position.

IP market structure

The evidence shows one potentially relevant corridor patent, [CN109545284A], apparently assigned to the Institute of Pharmacology and Toxicology of AMMS, and no project-held patents are provided. On this record, the only identifiable blocking IP is therefore this Chinese patent application covering a method and system for building an integrated drug information database from drug and target data: ingesting multiple external sources, standardizing and de-duplicating them, organizing them into drug-, target-, and interaction-oriented forms, linking records by key values, and presenting searchable, visualized drug/target relationships. The parts that matter most are not the specific `Node.js + Express + MongoDB` stack, but the claimed workflow of multi-source aggregation, normalization, keyed association, and query/visualization of drug-target information. The project’s freedom-to-operate posture looks mixed rather than clearly blocked. The immediate risk is concentrated in China because the cited asset is a CN application and is listed as pending, not granted, in the evidence. That reduces present enforceability certainty but still marks a meaningful corridor if the project does substantially the same thing: build a consolidated drug/target knowledge base from sources like DrugBank, ChEMBL, TCMID, PubChem, SMPDB, or KEGGdrug and expose linked search and network views. Outside China, this evidence alone does not establish a direct blocker. Even in China, the breadth suggested by the abstract and description may be vulnerable to narrowing in prosecution, because the disclosed invention reads like a relatively general data integration architecture. Design-around appears feasible. A project can reduce exposure by avoiding the specific “drug information form plus key-value association” structure, limiting itself to narrower use cases, relying on different data primitives or pipelines, avoiding the claimed visualization/query pattern, or framing the product as analytics over independently maintained source links rather than a unified drug-target database model. Technical differentiation should be practical here. The likely blocker also appears more licensable than strategically closed. The assignee is a research institution rather than an operating platform monopolist, and nothing in the evidence suggests an exclusivity-driven commercialization posture. So the corridor looks real but navigable: moderate patent adjacency, no clear hard block from the supplied record, and a plausible path either to design around or to obtain a license if needed.

Team / operational81

Team operational risk is high because the evidence is thin on the actual operating team, staffing depth, prior execution record, or institutional support. What is visible is a long-held founder thesis, a public launch narrative, and a beta product, but not evidence of repeatable delivery, customer support capacity, annotation operations, or resilience beyond key-person dependence.

Funding / capital58

Funding risk looks moderate. On one hand, this appears to be a software/infrastructure effort, so it likely does not require biotech-scale capital. On the other hand, the product thesis implies a long adoption curve, substantial AI/annotation costs, and a hard commercialization problem because academic incentives remain tied to conventional papers and journals. That combination can make it difficult to raise enough capital before clear usage or institutional traction appears.

Scientific panel

Mechanism plausibility62

The core mechanism is conceptually plausible for an information-infrastructure project: representing papers as argumentation graphs or nanopublication-like units could make hypotheses, experiments, results, conclusions, and evidence more navigable for humans and AI. Project-specific evidence supports that Singularis is explicitly pursuing PDF upload, graph visualization, and graph-based chat, and the team articulates a coexistence path rather than an immediate replacement of papers. However, the fetched evidence does not show that AI conversion is accurate enough, that graph structures preserve scientific meaning reliably, or that users understand papers materially better through the system.

Evidence base45

There is a visible beta product page and a team-authored project description, plus field-context literature showing that linked research, continuous publishing, computable knowledge, and agent-native research artifacts are active areas. That supports feasibility at the problem-framing level. The evidence base is still thin for Singularis itself: no benchmark dataset, accuracy evaluation, adoption metrics, controlled user study, independent product review, or quantified workflow improvement is included.

Methodological rigor20

The project-specific evidence describes a thesis and prototype but does not provide an experimental protocol, validation set, annotation guidelines, inter-rater agreement, blinded graph-quality assessment, controls against hallucinated links, statistical analysis, or pre-registered success criteria. The current evidence is therefore closer to product positioning than rigorous methodological validation.

Reproducibility15

No project-specific evidence shows independent replication, repeated internal validation, open benchmark outputs, downloadable graph conversions, or third-party audits of the paper-to-graph process. The team claims the format could help address reproducibility problems in science, but that is not evidence that Singularis' own method is reproducible.

Novelty58

The project combines several known ideas: semantic publishing, nanopublications, argumentation graphs, scientific annotation, and AI-assisted extraction from papers. Field-context evidence shows substantial prior work on decentralized linked research, continuous scientific publishing, computable knowledge, and agent-native artifacts, so the broad thesis is not wholly novel. Singularis may be novel in its specific product packaging around PDF upload, knowledge-graph visualization, and graph chat, but the evidence does not establish a defensible technical breakthrough.

Falsifiability70

The central claim is fairly testable: one can measure graph extraction accuracy against expert annotations, source-link fidelity, reading comprehension, time-to-answer, user retention, and cross-paper synthesis quality. The team description implies concrete outputs such as hypotheses, experiments, results, conclusions, and evidence links that can be checked. The score is limited because the fetched evidence does not specify target thresholds, benchmark corpora, or formal go/no-go criteria.

Breakthrough panel

Mechanism novelty54

The mechanism is a plausible recombination of known semantic-publishing, nanopublication, annotation, and AI extraction ideas rather than a wholly new mechanism. Singularis' specific paper-to-argumentation-graph workflow is project-specific, but field evidence shows adjacent work on decentralized linked research, continuous publishing, computable knowledge, and agent-native research artifacts.

Effect size25 projected percent reduction in time to triage or navigate a scientific paper if graph extraction is accurate38

The claimed effect could be meaningful: faster navigation of hypotheses, experiments, results, conclusions, and evidence than reading narrative papers. However, the fetched evidence shows positioning and a beta interface, not measured comprehension gains, accuracy benchmarks, retention, or workflow time savings. The score is therefore held down despite a potentially large target problem.

Cross-domain impact47

If reliable, structured paper graphs could help researchers, students, AI literature tools, peer review, and R&D knowledge management. Current evidence supports only a beta with PDF upload, graph viewing, and graph chat, so near-term cross-domain impact is more optionality than demonstrated adoption.

Future opening potential72

The long-run opening is stronger than the present evidence: if papers can be converted into accurate, inspectable graph objects, it could support graph-native publishing, claim-level review, machine-actionable research artifacts, and new contribution metrics. This remains conditional on accuracy, governance, and institutional adoption.

Time horizon~2 yr66

A first demonstrable result could arrive quickly because a public beta already exists and the next proof point could be an accuracy or usability benchmark rather than institutional transformation. Broader publishing-system impact would take much longer, so the score reflects near-term demo feasibility, not mature ecosystem change.

Paradigm shift signal63

The paradigm-shift claim is real: it challenges the assumption that the narrative paper should remain the primary unit of scientific knowledge. But the project itself frames change as evolutionary and paper-coexisting, and evidence does not yet show that users or institutions are moving away from paper-centric evaluation.

Investor panel

Most attractive
Regulatory pathway clarity (88)

This appears to be scholarly/research workflow software, not a therapeutic, diagnostic, or patient-facing medical product. No FDA/EMA pathway is needed for the product as evidenced. The score is high because regulatory burden is low, not because there is a formal regulatory strategy.

Most concerning
Customer validation signal (12)

There is a public beta and one repost/comment calling the work cool, but no evidence of paying users, pilots, LOIs, institutional adoption, retention, workflow metrics, or end-user case studies. The product page demonstrates availability more than demand.

Addressable market$8B62

The problem is broad: scientific publishing and research communication are structurally inefficient, with static PDFs contrasting with computational science workflows and limiting dissemination, reuse, and uptake. Singularis also targets both human readers and AI systems, which could expand the market beyond academics into R&D and education. However, no fetched evidence provides a market-size estimate, paid demand, or budget-owner mapping, so the TAM estimate is a rough software/research-infrastructure anchor rather than a cited market figure.

Defensibility28

The project has a coherent product thesis around argumentation graphs, nanopublication-like units, PDF upload, graph visualization, and graph chat, but the fetched evidence shows no Singularis-owned patents, exclusive dataset, proprietary benchmark, institutional data lock-in, or demonstrated extraction accuracy moat. Field-context evidence also shows many adjacent semantic publishing, linked-data, knowledge-graph, and agent-native research artifact efforts, which weakens presumed IP defensibility.

Team execution capacity22

Project-specific evidence identifies Peter Lidsky as the author/poster and shows a public beta site, but it does not establish a team, prior startup execution, shipped comparable infrastructure, production scale, or published technical validation by the team. The beta itself is positive but thin evidence for execution capacity.

Founder skin in the game35

The strongest signal is Peter Lidsky's public statement that he has carried the project for almost 10 years, which indicates reputational and sustained personal commitment. There is no fetched evidence of founder capital invested, salary sacrifice, full-time status, equity-vs-cash tradeoff, or other financial risk.

Customer validation signal12

There is a public beta and one repost/comment calling the work cool, but no evidence of paying users, pilots, LOIs, institutional adoption, retention, workflow metrics, or end-user case studies. The product page demonstrates availability more than demand.

Burn to breakeven$12M72

As a pure software platform, Singularis should be more capital efficient than biotech, hardware, or regulated devices. The main costs are engineering, AI inference/compute, data ingestion, product design, and sales into academia or R&D. Because there is no evidence of heavy wet-lab, clinical, or hardware requirements, the estimate uses the lower-middle SaaS benchmark band, but go-to-market into scholarly institutions may still be slow.

Time to value18 mo65

A beta website with upload, graphs, and chat suggests revenue experiments could begin relatively soon if the team can convert researchers, labs, or students into paid users. That said, the evidence does not show current revenue, pilots, or procurement channels, and academic publishing workflow adoption is likely slower than ordinary prosumer SaaS.

Regulatory pathway clarity88

This appears to be scholarly/research workflow software, not a therapeutic, diagnostic, or patient-facing medical product. No FDA/EMA pathway is needed for the product as evidenced. The score is high because regulatory burden is low, not because there is a formal regulatory strategy.

Competitive freedom34

The need is real, but competitive freedom is limited. Field evidence includes MyST/Curvenote for continuous scientific publishing, decentralized linked research/dokieli, Evidence Hub-style computable knowledge publication, nanopublication-like publishing, and agent-native research artifact proposals. Singularis may differentiate through AI-generated argumentation graphs over PDFs, but fetched evidence does not yet prove a hard-to-copy implementation or unique distribution path.

Asymmetric upside50×58

If Singularis became a graph-native layer for scientific knowledge, it could sit across publishing, search, education, peer review, and AI research agents. The upside is meaningful for a software platform, but the evidence currently shows a beta and thesis rather than adoption, network effects, or accuracy validation. Best-case outcome is therefore anchored as platform M&A rather than breakthrough-category dominance.

Exit landscape35

The fetched evidence does not include verified M&A or licensing comparables for scholarly communication infrastructure, AI research tools, or knowledge-graph publishing platforms. Adjacent field activity supports strategic relevance, but not a clear exit comp set. Exit potential likely depends on adoption by publishers, academic infrastructure vendors, research workflow platforms, or AI knowledge vendors.

Cost to commercialize$3M78

Commercial launch should be relatively low-capital because the current evidence shows a software beta rather than lab, manufacturing, or regulatory infrastructure. The main commercialization requirements are engineering, AI processing costs, security, data rights, and distribution. The score is capped because accurate scientific claim extraction and source-grounded graph generation may require substantial evaluation, domain tuning, and support.

Authors

No authors resolved yet.

Evidence

org record (1)
paper (12)
Journal of Global Health's GUidelines for Authors on Requesting and DIsclosing changes in Authorship Nominations (GUARDIAN).
Field contextfetched
https://pubmed.ncbi.nlm.nih.gov/41979923/
pmc5/30/202648,824 chars
Author guidelines in the AI era: Writing for readers, search engines, and reproducibility. Insights from editorial practice.
Field contextfetched
https://pubmed.ncbi.nlm.nih.gov/42046325/
europepmc5/30/20262,503 chars
patent (7)
project page (1)
Singularis: reforming the communication of scientific knowledge
Project specificfetched
https://singularis.ac/
direct5/30/2026532 chars
team project (1)
web (39)
wiki (13)
উইকিপিডিয়া:আলোচনাসভা/সংবাদ/সংগ্রহশালা ৬
Field contextfetched
https://bn.wikipedia.org/wiki/%E0%A6%89%E0%A6%87%E0%A6%95%E0%A6%BF%E0%A6%AA%E0%A6%BF%E0%A6%A1%E0%A6%BF%E0%A6%AF%E0%A6%BC%E0%A6%BE:%E0%A6%86%E0%A6%B2%E0%A7%8B%E0%A6%9A%E0%A6%A8%E0%A6%BE%E0%A6%B8%E0%A6%AD%E0%A6%BE/%E0%A6%B8%E0%A6%82%E0%A6%AC%E0%A6%BE%E0%A6%A6/%E0%A6%B8%E0%A6%82%E0%A6%97%E0%A7%8D%E0%A6%B0%E0%A6%B9%E0%A6%B6%E0%A6%BE%E0%A6%B2%E0%A6%BE_%E0%A7%AC
jina5/30/2026659,055 chars

★ AI estimate from available evidence — click any star for rationale.